- £4.07bn
- £5.06bn
- $3.16bn
- 83
- 52
- 46
- 67
REG - Hikma Pharmaceutical - Director/PDMR Shareholding
AnnouncementREG - Hikma Pharmaceutical - Director/PDMR Shareholding
AnnouncementREG - Hikma Pharmaceutical - Half-year Report
AnnouncementREG - Stock Exch Notice - Admission to ISM - 09/07/2025
AnnouncementREG - Hikma Pharmaceutical - Notice of Results
AnnouncementREG - Hikma Pharmaceutical - Publication of Offering Circular
AnnouncementREG - Hikma Pharmaceutical - Director/PDMR Shareholding
AnnouncementREG - Hikma Pharmaceutical - Director/PDMR Shareholding
AnnouncementREG - Hikma Pharmaceutical - Director/PDMR Shareholding
AnnouncementREG - Hikma Pharmaceutical - Fitch upgrades Hikma to ‘BBB’
AnnouncementREG - Hikma Pharmaceutical - Director/PDMR Shareholding
AnnouncementREG - Hikma Pharmaceutical - Medium-term Group guidance ahead of US site visit
AnnouncementREG - Hikma Pharmaceutical - Director/PDMR Shareholding
AnnouncementREG - Hikma Pharmaceutical - S&P upgrades Hikma to ‘BBB’
AnnouncementREG - Hikma Pharmaceutical - Settlement agreement for Xyrem® US lawsuits
AnnouncementREG - Hikma Pharmaceutical - Director/PDMR Shareholding
AnnouncementREG - Hikma Pharmaceutical - Result of AGM
AnnouncementREG - Hikma Pharmaceutical - Trading Statement
AnnouncementREG - Hikma Pharmaceutical - Director/PDMR Shareholding
Announcement